Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Sign Up to like & getrecommendations! Published in 2021 at "British journal of clinical pharmacology"
DOI: 10.1111/bcp.15034
Abstract: AIMS Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A used in the treatment of adult and paediatric patients with moderate-to-severe psoriasis. This analysis evaluated the pharmacokinetics (PK) of ixekizumab and the exposure-efficacy relationship… read more here.
Keywords: patients psoriasis; paediatric patients; exposure efficacy; efficacy ... See more keywords
Exposure–Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP
Sign Up to like & getrecommendations! Published in 2022 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01399-21
Abstract: An exposure–efficacy analysis of the phase 3 ASPECT-NP trial was performed to evaluate the relationship between plasma exposure of ceftolozane and tazobactam and efficacy endpoints (primary: 28-day all-cause mortality; key secondary: clinical cure at test-of-cure… read more here.
Keywords: ceftolozane tazobactam; efficacy; exposure efficacy;
Impact of antibiotic exposure on the efficacy of immune checkpoint blockade in MSI-H metastatic CRC.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.4_suppl.161
Abstract: 161Background: Immunotherapy has improved outcomes for many patients (pts) with advanced cancers found to be microsatellite instability high (MSI-H). However, not all MSI-H pts exhibit the same eff... read more here.
Keywords: immune checkpoint; efficacy immune; msi; exposure efficacy ... See more keywords